Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11951172 Therapeutic molecules that bind to LAG3 and PD1

Patent 11951172 was granted and assigned to Crescendo Biologics on April, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Crescendo Biologics

0

Current Assignee

Crescendo Biologics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

James Legg0

David Escors Murugarren0

Isabelle Osuch0

Angelica Sette0

Carolyn Edwards0

Yumin Teng0

Date of Patent

April 9, 2024

0

Patent Application Number

169699050

Date Filed

February 18, 2019

0

Patent Citations

US Patent 11236174 Therapeutic molecules

0

US Patent 11591398 Single domain antibodies to programmed cell death protein 1 (PD-1)

0

US Patent 11312771 Single-domain antibodies to programmed cell death 1 protein (PD-1), encoding nucleic acids and methods of using same

0

US Patent 7851598 Receptor modulators

0

US Patent 9872852 Compounds useful as immunomodulators

0

US Patent 10202458 IGF-1R antibody and its use as addressing vehicle for the treatment of cancer

0

US Patent 10323090 PD1 and/or LAG3 binders

0

US Patent 10975161 Molecules that bind prostate specific membrane antigen (PSMA)

0

Patent Primary Examiner

0

Patent abstract

The invention relates to LAG-3 binding agents, in particular variable heavy chain (V

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11951172 Therapeutic molecules that bind to LAG3 and PD1

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool